by
Loren Bonner, DOTmed News Online Editor | June 01, 2012
From the June 2012 issue of HealthCare Business News magazine
DMBN: Is there anything you’re particularly excited to see at this year’s SNM conference in Miami Beach?
GS: I’m excited about the same things I always see there, and that is to see so many nuclear medicine professionals from all around the world come to the largest meeting devoted to nuclear medicine/molecular imaging—and I really mean that sincerely. About half the attendees at the annual meeting come from beyond the U.S. and they bring knowledge and perspective that really enrich the meeting through their scientific presentations. Also, I’m always excited to see what is being shown on the exhibit floor because many times, companies introduce their newest technologies at SNM.
DMBN: What leaves you optimistic about the future of molecular imaging?
GS: We’ve seen FDA approval of new radiopharmaceuticals in the last year and we know that several more new radiopharmaceuticals are in the clinical trials pipeline and are likely to be approved in the near future. I’m also very excited about the potential clinical and research applications of PET/MR, which is another advance in the field and I also feel that the non-radioisotope-based molecular imaging technologies such as optimal imaging are maturing very quickly and they are likely going to be ready for clinical use in the near future as well.
Back to HCB News
